Commitment and investment to develop the use of Process Analytical Technology (PAT) is a primary reason why the pharmaceutical industry is able to find ways to streamline and improve manufacturing processes. However, there are significant challenges when implementing Process Analytical Technology (PAT) into larger-scale manufacturing, such as compatibility of measurement instrumentation with classified hazardous areas and the existing processing infrastructure. Even more important is how to sample the chemistry in situ. The majority of reactor vessels in commission today lack suitable entry points for the measurement technology that requires there modification or replacement, which can significantly increase project costs or prohibit implementation entirely.
May Ling Yeow, project & technology engineer, and her colleagues at Pfizer (Ruth Hardy, Paul Richards, Laura Aiken, Kyle Leeman, and Ian Clegg) overcame the challenge of implementing PAT in large scale manufacturing by using a novel in situ sampling approach. In a recent TCE article published in September, you can find out how they designed and implemented a base valve configuration with built-in online Infrared (IR) monitoring capability to realize the value of Process Analytical Technology (PAT) in the plant.